Your browser doesn't support javascript.
loading
Cardiovascular Disease Prevention: Risk Assessment.
Viera, Anthony J; Reamy, Brian V.
Afiliação
  • Viera AJ; Department of Family Medicine and Community Health - Duke University School of Medicine, DUMC 2914, Durham, NC 27710.
  • Reamy BV; Department of Family Medicine - Uniformed Services University School of the Health Sciences School of Medicine, 4301 Jones Bridge Rd, Bethesda, MD 20814.
FP Essent ; 520: 8-14, 2022 09.
Article em En | MEDLINE | ID: mdl-36069717
As part of the approach to primary prevention of cardiovascular disease (CVD), adults should have their CVD risk estimated using a population-appropriate risk equation. In the United States, the atherosclerotic cardiovascular disease (ASCVD) pooled cohort equations are recommended by the American College of Cardiology/American Heart Association (ACC/AHA) to estimate risk in patients ages 40 to 79 years. A 10-year ASCVD risk estimate of 20% or higher is considered high, and patients having this level of risk should be offered and counseled to receive statin therapy. A 10-year risk estimate of 7.5% to less than 20% is considered intermediate, and clinicians should discuss the potential benefits of statin therapy for primary prevention in the context of the patient's preferences and values. In some situations, use of CVD risk enhancers, particularly coronary artery calcium assessed by computed tomography, may help inform the clinician-patient discussion. All patients should be counseled about healthy lifestyle modifications to reduce CVD risk. The AHA's Life's Simple 7 defines ideal cardiovascular health as no tobacco use; ideal blood pressure, blood glucose, and cholesterol levels; adequate physical activity; weight management; and healthy diet. An 8th component (sleep) was very recently added and 4 of the original components have been updated. These metrics provide goals that can drive efforts toward primordial prevention (ie, keeping risk factors themselves from developing).
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Inibidores de Hidroximetilglutaril-CoA Redutases / Aterosclerose Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Inibidores de Hidroximetilglutaril-CoA Redutases / Aterosclerose Idioma: En Ano de publicação: 2022 Tipo de documento: Article